新桥生物(NovaBridge Biosciences)宣布,其核心候选药物Givastomig的注册性三期临床试验,预计最早将于2026年第四季度开始。这一关键性试验的启动,标志着该药物在特定适应症研发进程中迈入决定性阶段,为后续的监管申报和潜在商业化铺平道路。
新桥生物(NovaBridge Biosciences)宣布,其核心候选药物Givastomig的注册性三期临床试验,预计最早将于2026年第四季度开始。这一关键性试验的启动,标志着该药物在特定适应症研发进程中迈入决定性阶段,为后续的监管申报和潜在商业化铺平道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.